Farmas USA

IDRA
En PM, ya con los 100 primeros cromos, la tiran un 10%

OCAT

Ah, y otro filling interesante de ayer o anteayer ha sido este en el que cubren a la empresa esta http://investor-com.com/ frente a posibles responsabilidades legales.

Ocata has also agreed to reimburse InvestorCom, Inc. for certain reasonable out of pocket expenses and to indemnify InvestorCom, Inc. against certain liabilities in connection with its services, including certain liabilities under the federal securities laws.”

Puede que sean los que andan presionando con las llamadas. Obviamente, si tuvieran las cosas atadas no precisarían de estos servicios.

Unlike most of our competitors, InvestorCom is an independent firm providing the balance of a broad range of services in a focused team-driven environment.

The ability of corporations to identify which investors are influencing their share price and understand why they are doing so is the foundation of a successful investor relations program.

InvestorCom recognizes the link between the knowledge of shareholders and their trading behavior, and the effectiveness in being able to communicate with them. Our ability to timely and accurately identify “who” owns stock and “why” trading activity is occurring allows InvestorCom to provide clients with the highest level of market insight and the ability to look far beyond the mask of shares held in “street” name. At InvestorCom this is what we call “Shareholder Intelligence.” Simply stated, it’s the knowledge of who currently owns your stock, what their motivation is for trading in your stock, and, of equal importance, how to act on this information.

The following is a brief list of what we offer with our Stock Surveillance service:
•Daily Monitoring and Reporting
•Weekly Trading Memos
•Executive Monthly Summary
•Shareholder Profiles
•Institutional Targeting

http://ir.ocata.com/sec-filings/content/0001193125-16-421810/d108246dsc14d9a.htm

Revolutionary Neuroscience Technique Slated for Human Clinical Trials:
Optogenetics may treat chronic pain and other neurological disorders

http://linkis.com/com/9r1by

MSTX

Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%; top-line data anticipated Q2 2016
Enrollment in Phase 2a study of AIR001 in HFpEF is complete; top-line data expected this month

On January 7, 2016, the Company announced that its cash, cash equivalents and investment securities were approximately $41 million as of December 31, 2015.

The Second Amendment extended to January 31, 2016 the deadline for the Company’s vepoloxamer and AIR001 programs to achieve the clinical development milestones required to avoid prepayment to Hercules on April 30, 2016 of $10 million of the principal balance under the Loan Agreement.

http://ih.advfn.com/p.php?pid=nmona&article=69922410&xref=newsalerttweet&adw=1126416

Buenas tardes

En estas fechas estoy un poco desconectado... pero aún tengo un paquete en RIGL.

Hoy han anunciado que se presentan a una conferencia de JP Morgan y dan información de como van sus estudios...
http://www.prnewswire.com/news-releases/rigel-reviews-recent-progress-and-announces-presentation-at-the-34th-annual-jp-morgan-healthcare-conference-in-san-francisco-300200813.html

¿Alguien podría echarle un ojo y decirme que le parece?. A mi me da buena espina esta empresa... pero no sé, estas pequeñas farmas en cualquier momento te dan el susto.

Un saludo a todos

CLSN

Celsion (CLSN) Reports New Translational Data from GEN-1 Phase 1b; Immunologically Distinct IL-12 Protein Produced

Treatment with GEN-1 Results in Sustained, Targeted Production of Immunologically Active IL-12
Cytokine Activation to GEN-1 Immunotherapy is Limited to Targeted Area in the Peritoneum of Patients
Exciting Development Shows Potential for Significant Advantages over Recombinant IL-12 Dosage Options

http://investor.celsion.com/releaseDetail.cfm?ReleaseID=949315

No dicen nada negativo que haya podido ver en un vistazo rapido. Por lo demas los estudios siguen su curso segun agenda y pretenden iniciar una fase 2 este Q1 y finalizar reclutamiento de una fase 3 este mes.

En cualquier caso el mercado no esta para ser amable actualmente con las farmas, incluso cualquier new positiva va a ser ninguneada por lo general o la alegria sera escasa y durara poco. bueno, no esta amable con nada realmente.

RIGL

premarket NVAX 7.13 .... y los futuros no aflojan